MOESM1 of Positive association between baseline brachial–ankle pulse wave velocity and the risk of new-onset diabetes in hypertensive patients
Creators: name: Zhang, Yuanyuan
name: He, Panpan
name: Li, Youbao
name: Zhang, Yan
name: Li, Jianping
name: Liang, Min
name: Wang, Guobao
name: Tang, Genfu
name: Song, Yun
name: Wang, Binyan
name: Liu, Chengzhang
name: Liu, Lishun
name: Cui, Yimin
name: Wang, Xiaobin
name: Huo, Yong
name: Xu, Xiping
name: Qin, Xianhui
Publisher: name: figshare
Year: 2019
Subjects: subject: Medicine
subject: Neuroscience
subject: Physiology
subject: FOS: Biological sciences
subject: Biotechnology
subject: Chemical Sciences not elsewhere classified
subject: Sociology
subject: FOS: Sociology
subject: Mathematical Sciences not elsewhere classified
subject: Infectious Diseases
subject: FOS: Health sciences
subject: Computational Biology

description: Additional file 1. Table S1. Baseline characteristics of the study population by brachial–ankle pulse wave velocity (baPWV) quartiles. Table S2. Association between baseline brachial–ankle pulse wave velocity (baPWV) and new-onset diabetes during follow-up. Table S3. Association between baseline brachial–ankle pulse wave velocity (baPWV) and physician-diagnosed diabetes or use of glucose-lowering drugs during follow-up. Table S4. Association between baseline brachial–ankle pulse wave velocity (baPWV) and the change in fasting glucose among subjects without physician-diagnosed diabetes, or use of glucose-lowering drugs during follow-up. Table S5. Concomitant use of medications during the treatment period by the quartiles of baseline brachial–ankle pulse wave velocity (baPWV). Table S6. Association between baseline brachial–ankle pulse wave velocity (baPWV) and new-onset diabetes during follow up, with further adjustment for the use of calcium channel blockers or diuretics during the treatment period. Table S7. Association between baseline brachial–ankle pulse wave velocity (baPWV) and new-onset diabetes during follow-up in participants without the use of diuretics during the treatment period. Table S8. Association between baseline brachial–ankle pulse wave velocity (baPWV) and new-onset diabetes during follow-up, with further adjustment for the study drug (enalapril or enalapril-folic acid) compliance during the trial. Table S9. Association between baseline brachial–ankle pulse wave velocity (baPWV) and new-onset diabetes during follow-up, with further adjustment for alcohol consumption, family history of diabetes, physical activity and socioeconomic status. Table S10. Association between baseline brachial–ankle pulse wave velocity (baPWV) and new-onset diabetes during follow-up, with further adjustment for change in BMI (calculated as BMI at the exit visit minus that at baseline). Table S11. Association between baseline pulse pressure (PP) (both baseline PP and time-averaged PP during the treatment period) and new-onset diabetes during follow-up. Table S12. Association between baseline brachial–ankle pulse wave velocity (baPWV) and new-onset diabetes during follow up, with adjustment for pulse pressure (PP) with or without systolic blood pressure (SBP). Figure S1. Flow chart of the study participants. Figure S2. Association between baseline brachial–ankle pulse wave velocity (baPWV) and physician-diagnosed diabetes or use of glucose-lowering drugs during follow-up. Figure S3. Association between baseline brachial–ankle pulse wave velocity (baPWV) and the change in fasting glucose (fasting glucose at the exit visit minus that at baseline) among subjects without physician-diagnosed diabetes, or use of glucose-lowering drugs during follow-up.